Background. Several studies demonstrated superiority of drug-eluting stents compared to bare metal stents in relative simple lesions and patients.Aim. The aim of the study was to analyze the results of paclitaxel eluting stents in patients with complicated lesions or in diabetics and to compare with bear metal stent patients having similar characteristics. Patients were selected from the randomized TAXUS II study. Methods. The TAXUS II study was a randomized, prospective study in 536 patients evaluating immediate and 12 months results in patients implanted with slow and moderate release paclitaxel stent with versus bare metal stent. From the baseline population, the subgroups of patients with complicated lesion were selected as follows (Taxus vs Controls): diabetics (32 vs 40 patients), female (68 vs 59 pts) small vessel of <2.75mm (130 vs 145), lesion length of >10 mm (130 vs 140), multiple stents (14 vs 19), or use of GP IIb/IIIa inhibitors (41 vs 47 pts). Results were expressed as a target lesion revascularization (TLR) rate at a follow-up time of 12 months. Results. Table shows the TLR rate. 
Overall there was a 75% improvement for paclitaxel group compared to the bear metal stent group. Conclusions. The paclitaxel stent has proven its superiority over bear metal stent in terms of TLR at one year even in patients with complicated lesions, such as small vessel, long lesions or diabetics.
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Initial Background:Drug-eluting stents (DES) and other new coronary devices receive US approval based on randomized trials in selected pts. Subsequent device utilization and clinical outcomes in the broader range of patients treated with these devices is learned slowly from single-center registries or smaller randomized trials. The STENT Group was developed to provide a large, prospective registry to quickly evaluate the "real world"outcomes of new devices. Methods: Six regional centers representing a broad range of practice were selected. Data coordinators were assigned for prospective in-hospital and longterm clinical data collection in pts undergoing PCI. Data fields include baseline clinical profiles, lesion characteristics, procedural devices and medications, in-hospital outcomes and complications, and longterm follow-up at 3 and 9 months to retrieve major adverse cardiac events (MACE). Informed consent is obtained in all pts. All data is submitted by each center into a secure web-based central database.
Preliminary Results: As of this submission, a total of 1057 pts have been consented into the registry since approval of DES in May 2003. Stent utilization is shown below.
Conclusions:
The STENT Group represents a unique multicenter network of centers committed to the rapid "real world" evaluation of new coronary devices. An annual volume of 8000 consented PCI cases is projected, and acute and late outcomes on completed patients with DES will be reported at the time of presentation.
1044-59
The 
